all these are looking ripe for this week
ams ,dcd,hti,rgo,hrd,goal,ubc,and of course smith@nephew,slough estates,hawtins plc,hsbc,3ii,ng,sse,dsg. tips for the week free!!!!!!!!!!!!!!1

Excelent full year results from this company this morning..

Smith & Nephew reports steady growth
MoneyAM

Smith & Nephew today reported underlying group reovenue up 7% in Q4. Orthopaedics revenues increased by 6%, reflecting a strong US performance and Endoscopy delivered another good result growing revenues by 9%.

Advanced Wound Management grew revenues by 7%, driven by a strong European and rest of the world performance.

Trading margin of 23.2%, marginally up on last year, was impacted by NPWT investment, Plus and compliance costs.

EPS was maintained at 16.6 cents.

For the full-year, group revenue was up 13% to $3.8bn, with underlying growth of 6%.

Trading profit was up 10% to $776m, up 6% underlying.

EPS increased 7% to 55.6 cents.

Orthopaedics revenues grew at 5% (8% excluding Plus impact4), while Endoscopy finished the year with 8% growth.

Advanced Wound Management, at 7% growth, delivered its best growth performance for 5 years

Trading margin at 20.4%, masking the longer term operating efficiency improvements we have made to our businesses

The group increased the second interim dividend by 10% to 8.12 cents per share.

Commenting on the full year, David Illingworth, CEO, said: 'We finished the year in a positive frame of mind. We grew underlying sales for the year by 6%, with a similar increase in trading profit. All of our businesses reported underlying sales growth. These achievements are particularly notable against the backdrop of the slowdown in the global economy and a number of industry-wide and company specific issues.

We remain alert to any changes in the near-term outlook in our businesses and believe that our company-wide Earnings Improvement Programme, which we started two years ago, gives us a head start in dealing with any tougher operating climate.

We are focused on extending our track record of delivering innovative products, bringing clinical benefits to patients and economic benefits to healthcare providers. We put our customers first, listen to their needs and deliver on our promises. The Board has continued its policy of increasing, by 10%, the dividend which is declared in US dollars, creating a significant additional benefit for sterling-based shareholders. I am confident we will continue to deliver sustainable long-term growth for our shareholders.'

Chart says Buy..

Yep thats what I was thinking mitzy.

May be a bit late here gf but better late than never.

Welcome aboard mitzy.

1 year chart shows a base wedge formation and there could be explosive growth opwards through the uptrend top channel line.

Final Results.

Q4 Highlights

· Revenue $1,106 million, up 4% on a reported and 3% on an underlying basis
· Trading profit was $279 million
· Trading profit margin of 25.2%, exceeding Q4 expectation of 24%
· Orthopaedics delivered significant improvement in profitability quarter-on-quarter
· Endoscopy delivered good revenue growth and excellent trading profit margin
· Advanced Wound Management grew at more than twice the market rate
· EPSA was up at 21.9¢
· Proposed final dividend up 10% to 10.8 cents per share

Full Year Commentary

· Reported revenue of $4,270 million, up 8% on a reported and 4% on an underlying basis
· Reported trading profit was $961 million
· Trading margin 22.5%
· EPSA increased 1.2% to 74.5¢
· Strong cash generation, net debt reduced by $354 million to $138 million

Half Yearly Report

Q2 Financial Highlights
· Revenue of $1,029 million, up 2% on an underlying basis
· Trading profit of $234 million, up 6% on an underlying basis
· Trading profit margin up 80 bps to 22.7% as ASD restructuring benefits come through
· Strong performance from Sports Medicine Joint Repair and NPWT
· EPSA consistent at 18.1 cents
· Group moves to net cash of $150 million
· Interim dividend increased 50% to 9.9¢ and new progressive dividend policy

Smith & Nephew completes Healthpoint acquisition

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces the completion of the acquisition of substantially all the assets of Healthpoint Biotherapeutics ("Healthpoint"). The purchase price of $782 million in cash has been financed from Smith & Nephew's existing cash resources and bank facilities.

The acquisition gives Smith & Nephew a strong position in bioactives, the fastest growing area of advanced wound management.

Smith & Nephew said its full year profits to be at the lower end of its guided range after a third quarter where growth was flat outside US and emerging markets but its artificial hips business returned to growth. Revenue grew 3% to $1.15bn in the three months to 30 September, leading management to expect underlying revenue growth for the full year to be at the lower end of the 3-4% guided range, with profit margins to be at the lower end of the guided 20-70 basis points range.